The Strategic Imperative: Medical Writing in a Globalized Pharma Landscape for Enhanced Trust and Content Delivery
DOI:
https://doi.org/10.51137/wrp.ijdht.524Keywords:
Medical Writing, Pharmaceutical Industry, Regulatory Affairs, Global Health, Brand Trust, Artificial IntelligenceAbstract
The contemporary pharmaceutical landscape is characterised by globalised markets, stringent regulatory requirements, and an increasing demand for transparent and culturally sensitive communication. This article argues that professional medical writing is no longer merely a support function but a strategic imperative for pharmaceutical organisations seeking to effectively deliver content across multiple markets and cultivate enduring brand trust. We explore how medical writers facilitate accurate and compliant content localisation, ensure scientific integrity in publications, uphold regulatory standards, and foster meaningful engagement with healthcare professionals and patients. By meticulously translating complex scientific information into diverse, audience-specific formats, medical writers play a pivotal role in maintaining consistency, mitigating risks, and ultimately building a credible and trustworthy brand reputation across international boundaries.
References
Chen J, Luo X, Qiu H, Mackey V, Sun L, & Ouyang X. (2018). Drug discovery and drug marketing with the critical roles of modern administration. American Journal of Translational Research, 10(12), 4302–4312. https://pmc.ncbi.nlm.nih.gov/articles/PMC6325519/
Stremlau M, & Slusher BS. (2025). The potential of academic drug discovery: Successes and challenges. Expert Opinion on Drug Discovery, 20(9), 1093–1098. https://doi.org/10.1080/17460441.2025.2528125
Chorniy A, Bailey J, Civan A, & Maloney M. (2021). Regulatory review time and pharmaceutical research and development. Health Economics, 30(1), 113–128. https://doi.org/10.1002/hec.4180
Bedenkov A, Moreno C, Agustin L., et al. (2021). Customer centricity in medical affairs needs human-centric artificial intelligence. Pharmaceutical Medicine, 35(1), 21–29. https://doi.org/10.1007/s40290-020-00378-1
Thanimalai S, Choon WY, & Lee KK. (2021). Stakeholder views of managed entry agreements: A literature review of national studies. Health Policy Open, 2, Article 100032. https://doi.org/10.1016/j.hpopen.2021.100032
Hood MM, Sawhney G, Varma S, & Goyla K. (2024). Bridging the gap: A comprehensive review of the interrelation and intricacies of medical writing with medical communication in a healthcare ecosystem. Recent Updates in Diseases and Health Research, 9, 138–153. https://doi.org/10.9734/bpi/rudhr/v9/1166
Bernisson M, & Sismondo S. (2025). How big is the medical writing industry? Why it matters. Health Promotion International, 40(5), Article daaf146. https://doi.org/10.1093/heapro/daaf146
Koob C. (2021). Determinants of content marketing effectiveness: Conceptual framework and empirical findings from a managerial perspective. PLoS ONE, 16(4), Article e0249457. https://doi.org/10.1371/journal.pone.0249457
Kearney SJ, Lowe A, Lennerz JK., et al. (2021). Bridging the gap: The critical role of regulatory affairs and clinical affairs in the total product life cycle of pathology imaging devices and software. Frontiers in Medicine, 8, Article 765385. https://doi.org/10.3389/fmed.2021.765385
Chiodin D, Cox EM, Edmund AV, Kratz E, & Lockwood SH. (2019). Regulatory affairs 101: Introduction to investigational new drug applications and clinical trial applications. Clinical and Translational Science, 12(4), 334–342. https://doi.org/10.1111/cts.12635
Miyazawa M, Tanaka M, Tanaka Y, et al. (2025). Concordance between Pharmaceuticals and Medical Devices Agency review and Ministry of Health, Labour and Welfare decision among new drug applications in Japan. Clinical Pharmacology & Therapeutics, 117(2), 544–553. https://doi.org/10.1002/cpt.3485
Tang KWK, Millar BC, & Moore JE. (2023). Improving health literacy of antibiotic use in people with cystic fibrosis (CF)—Comparison of the readability of patient information leaflets (PILs) from the EU, USA and UK of 23 CF-related antibiotics used in the treatment of CF respiratory infections. JAC-Antimicrobial Resistance, 5(6), Article dlad129. https://doi.org/10.1093/jacamr/dlad129
Francer J, Izquierdo JZ, Music T, et al. (2014). Ethical pharmaceutical promotion and communications worldwide: Codes and regulations. Philosophy, Ethics, and Humanities in Medicine, 9, Article 7. https://doi.org/10.1186/1747-5341-9-7
Jones, D., O'Connor, A., Abgaz, Y. M., & Lewis, D. (2011). A semantic model for integrated content management, localisation and language technology processing. In Proceedings of the 2nd International Conference on Multilingual Semantic Web (pp. 38–49). CEUR Workshop Proceedings. http://ceur-ws.org/Vol-775/paper4.pdf.
Thompson J, Lynch M, Sullivan HW, Aikin KJ, Dolina S, & Brewington M. (2023). Complexity of data displays in prescription drug advertisements for healthcare providers. Therapeutic Innovation & Regulatory Science, 57(4), 712–716. https://doi.org/10.1007/s43441-023-00523-3
Noar SM, Harrington NG, & Aldrich RS. (2009). The role of message tailoring in the development of persuasive health communication messages. In Communication Yearbook (Vol. 33) (pp. 73–133). https://doi.org/10.1080/23808985.2009.11679085
Anand G, & Joshi M. (2019). Good publication practice guideline 3: Evolving standards for medical writers. Perspectives in Clinical Research, 10(1), 4–8. https://doi.org/10.4103/picr.PICR_31_18
Wedderkopp N, & Rutz E. (2024). Scientific integrity and transparency in academic writing: The foundation of credible science. Children, 11(10), Article 1191. https://doi.org/10.3390/children11101191
Ingate S, Bendall K, Long C, Fetterman K, Liles-Burden M, & Strauss C. (2025). Tracking a medicine's regulatory risk management commitments provides better transparency and oversight. Therapeutic Innovation & Regulatory Science, 59(5), 901–908. https://doi.org/10.1007/s43441-025-00825-8
Owusu-Asante M, Darko DM, Seaneke S, et al. (2025). Comparison of the review models and regulatory timelines of seven countries participating in the ECOWAS-MRH initiative: Identifying opportunities for improvement. Frontiers in Medicine, 12, Article 1587761. https://doi.org/10.3389/fmed.2025.1587761
von Bruchhausen T, & Prechtel K. (2015). Pharmacovigilance medical writing: An evolving profession. Medical Writing, 24(2), 66–71. https://doi.org/10.1179/2047480615Z.000000000287
Wong LP, Alias H, & Lee HY. (2025). Understanding public confidence in locally-produced mRNA vaccines: Insights for future pandemic preparedness. Human Vaccines & Immunotherapeutics, 21(1), Article 2573562. https://doi.org/10.1080/21645515.2025.2573562
Song M, Elson J, Nguyen T, Obasi S, Pintar J, & Bastola D. (2024). Exploring trust dynamics in health information systems: The impact of patients' health conditions on information source preferences. Frontiers in Public Health, 12, Article 1478502. https://doi.org/10.3389/fpubh.2024.1478502
Sharma S. (2010). How to become a competent medical writer? Perspectives in Clinical Research, 1(1), 33–37. https://doi.org/10.4103/2229-3485.71845
Conway A, Dowling M, & Devane D. (2019). Implementing an initiative promote evidence-informed practice: Part 2-Healthcare professionals' perspectives of the evidence rounds programme. BMC Medical Education, 19(1), Article 75. https://doi.org/10.1186/s12909-019-1488-z
Wager E, Middleton P, & Salisbury H. (2015). Good publication practice for communicating company-sponsored research: GPP3. Wiley-Blackwell. https://doi.org/10.7326/m15-0288
Hager Y. (2019). Medical Communications: The "Write" Career Path for You? Cold Spring Harbor perspectives in biology, 11(1), a032953. https://doi.org/10.1101/cshperspect.a032953
Aryal S, Blankenship JM, Bachman SL., et al. (2024). Patient-centricity in digital measure development: Co-evolution of best practice and regulatory guidance. NPJ Digital Medicine, 7(1), Article 128. https://doi.org/10.1038/s41746-024-01110-y
Efthymiou E. (2025). Integrating digital and narrative medicine in modern healthcare: A systematic review. Medical Education Online, 30(1), Article 2475979. https://doi.org/10.1080/10872981.2025.2475979
Howard J, & Cheung HC. (2024). Artificial intelligence in medical writing. AsiaIntervention, 10(1), 12–14. https://doi.org/10.4244/AIJ-E-23-00005
Yu S, & Hwang H. (2025). The ethics of using artificial intelligence in writing medical research papers. Kosin Medical Journal, 40(4), 270–279. https://doi.org/10.7180/kmj.24.140
Singh S, Kumar R, Maharshi V, et al. (2024). Harnessing artificial intelligence for advancing medical manuscript composition: Applications and ethical considerations. Cureus, 16(10), Article e71744. https://doi.org/10.7759/cureus.71744
Lam BD, Dupee D, Gerard M, & Bell SK. (2023). A Patient-Centered Approach to Writing Ambulatory Visit Notes in the Cures Act Era. Applied clinical informatics, 14(1), 199–204. https://doi.org/10.1055/s-0043-1761436
Timpe C, Stegemann S, Barrett A, & Mujumdar S. (2020). Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. British Journal of Clinical Pharmacology, 86(10), 2020–2027. https://doi.org/10.1111/bcp.14388
Fitzpatrick PJ. (2023). Improving health literacy using the power of digital communications to achieve better health outcomes for patients and practitioners. Frontiers in Digital Health, 5, Article 1264780. https://doi.org/10.3389/fdgth.2023.1264780
Berger ML, Sox H, Willke RJ, et al. (2017). Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiology and Drug Safety, 26(9), 1033–1039. https://doi.org/10.1002/pds.4297
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mitesh Hood (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
